Life Technologies Inks Deal with iPS Academia Japan | GenomeWeb

NEW YORK (GenomeWeb News) – Life Technologies today announced a worldwide, non-exclusive deal with iPS Academia Japan for its induced pluripotent stem cell patent portfolio.

The agreement grants Life Tech the rights to commercialize a range of products and services designed to create iPS cells and differentiate them into any cell type for drug discovery and pre-clinical research. Life Tech will also be able to provide iPS cell creation, differentiation, and screening services to the scientific community.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.